Scientists Find Potential Treatment Approach for FTD and ALS
luvqs / Pixabay

Scientists Find Potential Treatment Approach for FTD and ALS

According to a recent article in MedicalXpress, scientists have discovered a possible method of treating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The study was also published in Science…

Continue Reading Scientists Find Potential Treatment Approach for FTD and ALS
ICYMI: AIT-101 Earned Orphan Drug Designation in the EU for ALS in March 2024
Capri23auto / Pixabay

ICYMI: AIT-101 Earned Orphan Drug Designation in the EU for ALS in March 2024

Historically, it has been difficult to incentivize companies to develop therapies for rare or “orphan” conditions. The National Conference of State Legislatures (NCSL) explains that “orphan” conditions are: neglected conditions…

Continue Reading ICYMI: AIT-101 Earned Orphan Drug Designation in the EU for ALS in March 2024
Prilenia Therapeutics Announces Data Supporting Initiation of Phase III ALS Study
source: shutterstock.com

Prilenia Therapeutics Announces Data Supporting Initiation of Phase III ALS Study

Prilenia Therapeutics, Waltham, Massachusetts and Naarden, Netherlands is a biotechnology company with a focus on developing therapeutics to treat neurodevelopmental disorders and neurodegenerative diseases. Prilenia presented data this month at…

Continue Reading Prilenia Therapeutics Announces Data Supporting Initiation of Phase III ALS Study
Pseudobulbar Affect: Six Signs to Watch Out For
source: shutterstock.com

Pseudobulbar Affect: Six Signs to Watch Out For

Strokes, traumatic brain injuries, amyotrophic lateral sclerosis, Alzheimer's disease, and multiple sclerosis all share something in common: they all have profound effects on the brain and its function. They can…

Continue Reading Pseudobulbar Affect: Six Signs to Watch Out For
EMA Issues Negative Opinion on AMX003 to Treat Adults with Amyotrophic Lateral Sclerosis (ALS)
source: pixabay.com

EMA Issues Negative Opinion on AMX003 to Treat Adults with Amyotrophic Lateral Sclerosis (ALS)

The long-awaited decision by the European committee CHMP was announced recently by Amylyx Pharmaceutical (the Company) based in Cambridge, Massachusetts just as anticipated. The EMA issued its negative opinion of…

Continue Reading EMA Issues Negative Opinion on AMX003 to Treat Adults with Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis Drug Developers Set Their Sights on a New Treatment Target
source: pixabay.com

Amyotrophic Lateral Sclerosis Drug Developers Set Their Sights on a New Treatment Target

On March 22, 2023, via PRNewswire, the FDA announced that its CNS Drugs Advisory Committee voted unanimously in favor of a potential accelerated approval of tofersen to treat people with…

Continue Reading Amyotrophic Lateral Sclerosis Drug Developers Set Their Sights on a New Treatment Target
Machine Learning Helps Identify Patterns of Progression in ALS
https://unsplash.com/photos/w7ZyuGYNpRQ

Machine Learning Helps Identify Patterns of Progression in ALS

According to a story from myscience.org, neurodegenerative diseases, such as amyotrophic lateral sclerosis, are diseases that progressively worsen over time. However, progression in this disease is not consistent across all…

Continue Reading Machine Learning Helps Identify Patterns of Progression in ALS
A New Treatment for Amyotrophic Lateral Sclerosis Gets Approved, but Trial Results Are Spotty
source: pixabay.com

A New Treatment for Amyotrophic Lateral Sclerosis Gets Approved, but Trial Results Are Spotty

According to a story from CNN, a new treatment was recently approved by the US Food and Drug Administration (FDA) for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's…

Continue Reading A New Treatment for Amyotrophic Lateral Sclerosis Gets Approved, but Trial Results Are Spotty